FDA
-
-
-
-
-
-
-
Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes
-
-
-
-
-
-
-
Fractyl Health reports weight maintenance data from Revita procedure study
-
-
-
-
-
-
-
Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth
-
-
-
-
-
-
-
Fractyl Health Reports Potent and Durable Two-Year Real-World Outcomes with Revita® Showing Sustained Weight Loss and Improved Glucose Control After a Single Procedure
-
-
-
-
-
-
-
Fractyl Health (GUTS) Advances Rejuva Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes
-
-
-
-
-
-
-
Fractyl Health Announces Positive Initial Clinical Results Demonstrating Weight Maintenance Following GLP-1 Discontinuation and Revita Procedure in First Patient of the REVEAL-1 Cohort
-
-
-
-
-
-
-
Fractyl Health Announces Clinical Results from German Real-World Registry Showing Meaningful and Sustained Weight Loss for at Least One Year After a Single Revita® Endoscopic Procedure
-
323,589 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

